-
放射性碘治疗Graves甲状腺功能亢进症(甲亢)已为人们所熟知。已有研究证实,放射性碘治疗Graves甲亢的有效性取决于其在甲状腺内的滞留量、有效半衰期、治疗前抗甲状腺药物(antithyroid drugs,ATD)的使用、甲状腺肿的大小和甲状腺24 h摄碘率等因素;而放射性碘治疗Graves甲亢前停用ATD以及放射性甲状腺炎,则可能导致放射性碘治疗后甲亢病情的短暂恶化[1-5]。国内外研究证实,碳酸锂具有提高甲状腺摄碘率、延长放射性碘在甲状腺内的有效半衰期等作用,有益于Graves甲亢的放射性碘治疗[6-12]。但因对碳酸锂治疗不良反应的担心,以及在何时开始服用、服用多久和放射性碘治疗结果评价等方面尚存争议,因此,长期以来就放射性碘治疗Graves甲亢常规辅以碳酸锂的治疗仍未获得一致意见。本文通过对可查询到的近十余年已发表文献的分析,拟就碳酸锂在放射性碘治疗Graves甲亢中的应用情况作一梳理,以期能更为清晰的认识其应用价值,充分发挥其在放射性碘治疗Graves甲亢中的作用,使Graves甲亢的放射性碘治疗更趋完善。
131I治疗Graves甲状腺功能亢进症中碳酸锂的应用
Application of lithium carbonate on radioiodine treatment of Graves'hyperthyroidism
-
摘要: 131I治疗Graves甲状腺功能亢进症(甲亢)的有效性取决于其在甲状腺内的滞留时间,且受治疗前抗甲状腺药物使用、肿大甲状腺容积和甲状腺24 h摄碘率等因素的影响。锂具有阻止有机碘和甲状腺激素自甲状腺内释出的作用而不影响甲状腺对131I的摄取,因此,131I治疗Graves甲亢前后辅以短程、小剂量碳酸锂,具有提高甲状腺摄碘率、延长131I在甲状腺内的有效半衰期的作用。使用碳酸锂辅助131I治疗Graves甲亢可增加甲状腺的受照剂量,从而减少有效半衰期短的患者服用131I的量和全身放射性照射量,并改善甲亢治愈率。131I辅以碳酸锂短程治疗因甲状腺毒症得到快速控制并避免了因131I治疗前抗甲状腺药物停用、不能耐受或无效的患者短期甲状腺毒症的恶化,和防止131I治疗后血清甲状腺激素水平短期升高,而被认为是有益的。另外,就快速控制甲亢而言,不管甲状腺肿的大小,碳酸锂均可增强131I治疗的有效性,同时也可提高巨大甲状腺肿患者甲亢的永久控制率。由于碳酸锂有助于预防放射性碘相关的血清游离甲状腺激素浓度的升高并可加强甲状腺毒症的控制,这对年长、严重甲亢、有心血管疾病或其他严重非甲状腺疾病基础的高危患者来说特别重要,因为,即便是甲状腺毒症的一个短暂恶化,也可能导致严重的后果。131I治疗Graves甲亢前后辅以小剂量碳酸锂治疗安全有效。Abstract: Effectiveness of radioiodine for Graves' hyperthyroidism depends on retention time of 131I in the thyroid, and may be effected by several factors, including previous treatment with antithyroid drugs, goiter volume, 24 h thyroidal radioactive iodine uptake and so on. A short course of therapy with low dose of lithium carbonate increased retention of 131I in the thyroid and prolong the intrathyroidal effective half-life of 131I before and after 131I therapy in patients with Graves'disease, because of the actions that lithium blocks the release of organic iodine and thyroid hormone from the thyroid gland without affecting thyroidal radioactive iodine uptake. Therefore, using lithium as adjunct to radioiodine therapy increases the radiation dose delivered to the thyroid, to result in reduced the activity required and whole-body radiation dose in patients with very short effective half-life, and so improve the cure rate of hyperthyroidism. A short course of lithium carbonate therapy can be considered a useful adjunct to 131I therapy for obtaining a more rapid control of thyrotoxicosis and avoiding its transient exacerbation because of methimazole withdrawal prior to 131I administration or in patients who cannot tolerate or do not respond to antithyroid drugs, and for helping to prevent the radioiodine-associated increase in serum free thyroid hormone concentrations. In addition, lithium carbonate enhances the effectiveness of 131I therapy, in terms of prompter control of hyperthyroidism in patients with small or large goiters. At the same time, lithium also may increases the rate of permanent control of hyperthyroidism in patients with large goiters. In summary, in the short-term lithium plays an important role as an adjunct to 131I, since it helps to prevent the 131I-associated increase in serum free thyroid hormone concentrations and allows a more prompt control of thyrotoxicosis. This is of particular importance in highrisk patients, such as the elderly, those with severe hyperthyroidism, underlying cardiovascular disorders, or other severe nonthyroidal illness for whom even a transient exacerbation of the thyrotoxicosis may be dangerous. Treatment with a relatively low dose of lithium before and after 131I therapy offers a safe and effective alternative means of controlling thyrotoxicosis in patients with Graves disease.
-
Key words:
- Graves disease /
- Iodine radioisotopes /
- Brachytherapy /
- Lithium carbonate /
- Chemotherapy, adjuvant
-
[1] Akin F, Yaylali GF, Bastemir M. The use of lithium carbonate in the preparation for definitive therapy in hyperthyroid patients. Med Princ Pract, 2008, 17(2): 167-170. doi: 10.1159/000112975 [2] Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves'hyperthyroidism. J Clin Endocrinol Metab, 1999, 84(2): 499-503. [3] Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid, 2002, 12(5): 399-405. doi: 10.1089/105072502760043486 [4] Dunkelmann S, Künstner H, Nabavi E, et al. Lithium as an adjunct to radioiodine therapy in Graves'disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?. Nuklearmedizin, 2006, 45(5): 213-218. doi: 10.1055/s-0038-1625222 [5] 王长修. 低摄131I率Graves病患者131I治疗时加用碳酸锂的临床价值. 中国误诊学杂志, 2006, 6(1): 32. doi: 10.3969/j.issn.1009-6647.2006.01.015
[6] Bogazzi F, Bartalena L, Campomori A, et al. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves'disease. J Clin Endocrinol Metab, 2002, 87(10): 4490-4495. doi: 10.1210/jc.2002-020580 [7] Ng YW, Tiu SC, Choi KL, et al. Use of lithium in the treatment of thyrotoxicosis. Hong Kong Med J, 2006, 12(4): 254-259. [8] Hoogenberg K, Beentjes JA, Piers DA. Lithium as an adjunct to radioactive iodine in treatment-resistant Graves thyrotoxicosis. Ann Intern Med, 1998, 129(8): 670. [9] Barbaro D, Grosso M, Boni G, et al. Recombinant hurman TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer the effect of pre-treatment with furosemide and furosemide plus lithium. Eur J Nucl Med Mol Imaging, 2010, 37(2): 242-249. doi: 10.1007/s00259-009-1254-2 [10] 李舜, 林映芬, 张家云, 等. 碳酸锂与丙基硫氧嘧啶对Graves病重型甲亢131碘疗效影响的比较. 中国现代医学杂志, 2005, 15(19): 2963-2965.
[11] 杨宾, 王伟, 翁孝刚, 等. 131I联合碳酸锂治疗Graves病疗效观察. 中国误诊学杂志, 2006, 6(11): 2111-2112. doi: 10.3969/j.issn.1009-6647.2006.11.061
[12] 赵辉, 张智勇, 徐晓红, 等. 131I合并小剂量碳酸锂治疗老年性甲状腺机能亢进的临床探讨. 临床内科杂志, 2007, 24(10): 716. doi: 10.3969/j.issn.1001-9057.2007.10.029
[13] Tang SW. Using lithium. Hong Kong Med J, 2006, 12(4): 253. [14] Kirov G. Thyroid disorders in lithium-treated patients. J Affect Disord, 1998, 50(1): 33-40. doi: 10.1016/S0165-0327(98)00028-7 [15] Dalan R, Leow MK, Jong M. Multiple endocrinopathies associated with lithium therapy. Endocr Pract, 2007, 13(7): 758-763. doi: 10.4158/EP.13.7.758 [16] Saunders BD, Saunders EF, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg, 2009, 33(11): 2314-2323. doi: 10.1007/s00268-009-9942-4 [17] Arlt S, Burkhardt D, Wiedemann K. Thyrotoxicosis after iodine contrast medium administration: rapid mood swing to mania and subsequent psychotic depression in a patient with bipolar disorder during lithium therapy. Pharmacopsychiatry, 2008, 41(4): 163-165. doi: 10.1055/s-2008-1076723 [18] Cayköylü A, Capolu I, Unüvar N, et al. Thyroid abnormalities in lithium-treated patients with bipolar affective disorder. J Int Med Res, 2002, 30(1): 80-84. doi: 10.1177/147323000203000112 [19] 管昌田. 131I治疗甲亢的最佳化. 国外医学·放射医学核医学分册, 1997, 21(5): 252-256.
[20] Mijnhout GS, Franken AA. Antithyroid drug regimens before and after 131I-therapy for hyperthyroidism: evidence-based?. Neth J Med, 2008, 66(6): 238-241. [21] Dunkelmann S, Kuenstner H, Nabavi E, et al. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves'disease. Eur J Nucl Med Mol Imaging, 2007, 34(2): 228-236. doi: 10.1007/s00259-006-0234-z [22] Burch HB, Solomon L, Cooper DS, et al. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after(131)I ablation for Graves' disease. J Clin Endocrinol Metab, 2001, 86(7): 3016-3021. [23] Bogazzi F, Bartalena L, Pinchera A, et al. Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid, 2002, 12(12): 1153-1154. doi: 10.1089/105072502321085298 [24] 查金顺, 张桂仙, 舒娜翎, 等. 甲亢用131I治疗前后动态检测甲状腺功能变化的临床研究. 标记免疫分析与临床, 1999, 6(3): 135-140.
[25] Turner JG, Brownlie BE, Rogers TG. Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. Lancet, 1976, 1(7960): 614-615. [26] Vannucchi G, Chiti A, Mannavola D, et al. Radioiodine treatment of non-toxic multinodular goitre: effects of combination with lithium. Eur J Nucl Med Mol Imaging, 2005, 32(9): 1081-1088. doi: 10.1007/s00259-005-1818-8 [27] Oszukowska L, Knapska-Kucharska M, Makarewicz J, et al. The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment((131)I) in hyperthyroid patients. Endokrynol Pol, 2010, 61(1): 56-61.
计量
- 文章访问数: 2176
- HTML全文浏览量: 759
- PDF下载量: 4